Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates ...

Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Scientists at the Salk Institute for Biological Studies and Sanford Burnham Prebys explore genetic factors in separate papers ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...

Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare ...

Boston-based Life Biosciences is testing whether reprogramming human cells can slow or even reverse the effects of aging. Unsplash Life Biosciences, a Boston-based biotechnology company founded in ...

For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

Aging has long been seen as a natural, unstoppable part of life. From the moment we're born, our bodies transform — first through growth, then through gradual decline. Over time, stamina wanes, ...